Growth Metrics

Castle Biosciences (CSTL) Equity Income (2024 - 2025)

Castle Biosciences' Equity Income history spans 2 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, Equity Income fell 430.45% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached $1.5 million, up 164.14%, while the annual FY2025 figure was $1.5 million, 164.14% up from the prior year.
  • Equity Income for Q4 2025 was -$1.8 million at Castle Biosciences, down from $3.5 million in the prior quarter.
  • Across five years, Equity Income topped out at $3.5 million in Q3 2025 and bottomed at -$1.8 million in Q4 2025.